Reduced Likelihood of Hospitalization With the JN.1 or HV.1 Severe Acute Respiratory Syndrome Coronavirus 2 Variants Compared With the EG.5 Variant.

Autor:	Levy ME; Helix, San Mateo, California, USA., Chilunda V; Helix, San Mateo, California, USA., Davis RE; Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, USA., Heaton PR; Department of Pathology and Laboratory Medicine, HealthPartners, Bloomington, Minnesota, USA., Pawloski PA; HealthPartners Institute, Minneapolis, Minnesota, USA., Goldman JD; Swedish Center for Research and Innovation, Providence Swedish Medical Center, Seattle, Washington, USA.; Division of Allergy and Infectious Disease, University of Washington, Seattle, Washington, USA., Schandl CA; Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., McEwen LM; Helix, San Mateo, California, USA., Cirulli ET; Helix, San Mateo, California, USA., Wyman D; Helix, San Mateo, California, USA., Rossi AD; Helix, San Mateo, California, USA., Dai H; Helix, San Mateo, California, USA., Isaksson M; Helix, San Mateo, California, USA., Washington NL; Helix, San Mateo, California, USA., Basler T; Helix, San Mateo, California, USA., Tsan K; Helix, San Mateo, California, USA., Nguyen J; Helix, San Mateo, California, USA., Ramirez J; Helix, San Mateo, California, USA., Sandoval E; Helix, San Mateo, California, USA., Lee W; Helix, San Mateo, California, USA., Lu J; Helix, San Mateo, California, USA., Luo S; Helix, San Mateo, California, USA.
Jazyk:	angličtina
Zdroj:	The Journal of infectious diseases [J Infect Dis] 2024 Nov 15; Vol. 230 (5), pp. 1197-1201.
DOI:	10.1093/infdis/jiae364
Abstrakt:	Within a multistate viral genomic surveillance program, we evaluated whether proportions of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections attributed to the JN.1 variant and to XBB-lineage variants (including HV.1 and EG.5) differed between inpatient and outpatient care settings during periods of cocirculation. Both JN.1 and HV.1 were less likely than EG.5 to account for infections among inpatients versus outpatients (adjusted odds ratio [aOR], 0.60 [95% confidence interval (CI), .43-.84; P = .003] and 0.35 [.21-.58; P < .001], respectively). JN.1 and HV.1 variants may be associated with a lower risk of severe illness. The severity of coronavirus disease 2019 may have attenuated as predominant circulating SARS-CoV-2 lineages shifted from EG.5 to HV.1 to JN.1. Competing Interests: Potential conflicts of interest . M. E. L., V. C., L. M. M., E. T. C., D. W., A. D. R., H. D., M. I., N. L. W., T. B., K. T., J. N., J. R., E. S., W. L., J. L., and S. L. are employees of Helix. M. E. L., E. T. C., D. W., M. I., J. L., and S. L. report support for attending meetings and/or travel from Helix. M. E. L., E. T. C., D. W., A. D. R., M. I., N. L. W., W. L., J. L., and S. L. report stock or stock options from Helix. M. E. L., M. I., W. L., and S. L. report contracted research from Pfizer. M. E. L., M. I., W. L., and S. L. report contracted research from the Centers for Disease Control and Prevention. M. E. L. reports contracted research and travel support from Novavax. R. E. D. reports consulting fees from Health Advances. P. R. H. reports contracted research from Seegene USA and Helix. J. D. G. reports contracted research from Helix, Gilead, Eli Lilly, and Regeneron; grants from Merck (BARDA) and Gilead; speaking honoraria and personal fees from Gilead Sciences and Eli Lilly; and collaborative services agreements with Adaptive Biotechnologies, Monogram Biosciences, and LabCorp; and service as a speaker or advisory board member for Gilead and Eli Lilly. C. A. S. reports giving educational lectures sponsored by Eli Lilly. M. I., N. L. W., and S. L. report patents pending or issued to Helix (M. I. and S. L.: US-11776694-B2 and US-20230178236-A1). P. A. P. reports no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu